NUC-1031 in biliary tract cancer: from bench to bedside and back?

Abstract

In preclinical models of biliary tract cancer, NUC-1031 showed less potency than gemcitabine, no correlation with potential biomarkers and only moderate additive interaction in combination with cisplatin. These findings should prompt further careful pharmacological and translational studies to better define the purported therapeutic advantage of NUC-1031 over gemcitabine. That would be a more cautious approach than the phase III clinical trial which is planning to enrol 828 patients with biliary tract tumours to compare gemcitabine/cisplatin "conventional" treatment with or without NUC-1031.

• Authors: Lenka N C Boyd, Godefridus J Peters, Geert Kazemier, Elisa Giovannetti
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 85 Issue 6 Pg. 1011-1014 (06 2020) ISSN: 1432-0843 [Electronic] Germany
• PMID: 32476108 (Publication Type: Editorial, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• NUC-1031
• Cytidine Monophosphate

Topics

• Antineoplastic Agents (therapeutic use)
• Biliary Tract Neoplasms (drug therapy, pathology)
• Cytidine Monophosphate (analogs & derivatives, therapeutic use)
• Humans
• Prognosis
• Translational Research, Biomedical